Navigation Links
Sunesis Pharmaceuticals Focuses Resources on Development of Voreloxin (Formerly SNS-595)
Date:6/3/2008

inary data and trends may not be predictive of future data or results; the risk that Sunesis' preclinical studies and clinical trials may not satisfy the requirements of the FDA or other regulatory agencies; risks related to the conduct of Sunesis' clinical trials and manufacturing; the risk that Sunesis may not be able to monetize its fragment-based drug discovery capabilities and/or intellectual property portfolio; the risk that Sunesis' restructuring costs may be greater than anticipated; the risk that Sunesis' workforce reduction and any future workforce and expense reductions may have an adverse impact on Sunesis' internal programs, Sunesis' ability to hire and retain key personnel and may be distracting to management; and risks related to Sunesis' need for additional funding. These and other risk factors are discussed under "Risk Factors" and elsewhere in Sunesis' Annual Report on Form 10-K for the year ended December 31, 2007, Sunesis' Quarterly Report on Form 10-Q for the quarter ended March 31, 2008 and other filings with the Securities and Exchange Commission. Sunesis expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward- looking statements contained herein to reflect any change in the company's expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based.


'/>"/>
SOURCE Sunesis Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Sunesis Pharmaceuticals Presents Updated Clinical Data From Ongoing Phase 2 Trial of Voreloxin (Formerly SNS-595) in Ovarian Cancer Patients at the 44th ASCO Annual Meeting
2. Sunesis Pharmaceuticals to Present Interim Clinical Data From Voreloxin (Formerly SNS-595) Ovarian Cancer Trial at 44th ASCO Annual Meeting and Acute Myeloid Leukemia Trials at 13th EHA Congress
3. Sunesis Pharmaceuticals Initiates Phase 2 Clinical Trial of Voreloxin (SNS-595) in Acute Myeloid Leukemia
4. Sunesis Pharmaceuticals Reports Data from Nonclinical Studies of SNS-032 at the Annual Meeting of the American Association for Cancer Research
5. Sunesis Pharmaceuticals to Present Non-Clinical Data at the Annual Meeting of the American Association for Cancer Research
6. Sunesis Pharmaceuticals Reports Positive Interim Data for SNS-595 Single-Agent Activity in Platinum-Resistant Ovarian Cancer
7. Sunesis Pharmaceuticals to Present Data on Two Product Candidates at the 49th Annual Meeting of the American Society of Hematology
8. Sunesis Pharmaceuticals Reports Preliminary SNS-595 Activity in Ovarian Cancer Clinical Trial at AACR-NCI-EORTC International Conference
9. Sunesis Pharmaceuticals Commences Clinical Trials of SNS-595 and SNS-314
10. Celator(R) Pharmaceuticals Announces Positive Phase 2 Results for CPX-1 in Treatment of Colorectal Cancer
11. Keryx Biopharmaceuticals, Inc. Announces Phase 2 Results on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory Waldenstroms Macroglobulinemia at the 44th Annual Meeting of the American Society of Clinical Oncology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2015)... 28, 2015 Voalte, the leader in ... in purpose-built wireless communications, today announced that Bay ... 104-bed acute-care facility in Webster, Texas ... One™ solution on Spectralink PIVOT™ purpose-built smartphones for ... Voalte a member of its AIMS Partner Program ...
(Date:7/28/2015)... July 21, 2015 Research and Markets ... the "Pharmaceutical Industry in China to 2020: ... Biopharma Companies, Industry Trends, Environment, Regulation, Market Drivers, ... offering. This report tackles not ... China but also home grown companies ...
(Date:7/28/2015)... YORK , July 28, 2015 /PRNewswire/ ... a new research report with market overview, ... share, forecast, porter analysis, recent developments, competitive ... Global Industry Insight: Human Insulin Market ...      (Logo: http://photos.prnewswire.com/prnh/20150727/756778) Explore ...
Breaking Medicine Technology:Bay Area Regional Medical Center Is First to Use Spectralink PIVOT with Voalte One for Caregiver Communication 2Bay Area Regional Medical Center Is First to Use Spectralink PIVOT with Voalte One for Caregiver Communication 3Pharmaceutical Industry in China to 2020: Market to Increase Dramatically to $200 Billion 2Global Human Insulin Market (Size of $24 billion in 2014) to Witness 13% CAGR During 2015 - 2020 2Global Human Insulin Market (Size of $24 billion in 2014) to Witness 13% CAGR During 2015 - 2020 3Global Human Insulin Market (Size of $24 billion in 2014) to Witness 13% CAGR During 2015 - 2020 4Global Human Insulin Market (Size of $24 billion in 2014) to Witness 13% CAGR During 2015 - 2020 5
... -- China Medical Technologies, Inc. (the "Company") (Nasdaq: ... in-vitro diagnostic ("IVD") company, today announced that its ... ("GP Medical") and Beijing Yuande Bio-Medical Engineering Co., ... 415th, respectively, in the Deloitte Technology Fast 500 ...
... SUNNYVALE, Calif., Dec. 5, 2010 Pharmacyclics, Inc. (Nasdaq: ... Chronic Lymphocytic Leukemia (CLL) presentations at the American Society ... PCI-32765.  Two presentations report preclinical data, and one presentation ... patients with CLL or Small Lymphocytic Lymphoma (SLL) treated ...
Cached Medicine Technology:China Medical Technologies Announces its Subsidiaries, GP Medical and Beijing Yuande, Ranked 12th and 415th, respectively, in Deloitte Technology Fast 500 Asia Pacific 2010 Program 2Pharmacyclics Reports CLL Results from Preclinical and Clinical Studies of its Btk Inhibitor PCI-32765 2Pharmacyclics Reports CLL Results from Preclinical and Clinical Studies of its Btk Inhibitor PCI-32765 3Pharmacyclics Reports CLL Results from Preclinical and Clinical Studies of its Btk Inhibitor PCI-32765 4Pharmacyclics Reports CLL Results from Preclinical and Clinical Studies of its Btk Inhibitor PCI-32765 5Pharmacyclics Reports CLL Results from Preclinical and Clinical Studies of its Btk Inhibitor PCI-32765 6Pharmacyclics Reports CLL Results from Preclinical and Clinical Studies of its Btk Inhibitor PCI-32765 7
(Date:7/28/2015)... ... 2015 , ... Healthpointe ’s Cosmetic Laser Institute in Anaheim is now ... and reduces the appearance of fine lines and wrinkles. , According to the Allergan ... add volume to your cheek area to correct age-related volume loss in adults over ...
(Date:7/28/2015)... ... 28, 2015 , ... On July 16th NPR reported needle exchange ... proposed bills and laws revolving the implementation of a small pilot program in Miami-Dade ... are continuing to hand out clean needles to drug users who are addicted to ...
(Date:7/28/2015)... PAUL, Minn. (PRWEB) , ... July 28, 2015 ... ... workflow company Kinetic Data announced that Schneider Electric has completed its upgrade ... Electric is a global organization with more than 170,000 employees in 134 countries ...
(Date:7/28/2015)... ... July 28, 2015 , ... Safeguard ... authorized the Company, from time to time and depending on market conditions, to ... to $25 million. Repurchases will be made in open market or privately negotiated ...
(Date:7/28/2015)... ... , ... Women fear developing Alzheimer's disease more than having a heart attack ... are treatable, but there is little an individual can do to arrest the progress ... clinical trial, reports the July 2015 Harvard Women's Health Watch . , "There ...
Breaking Medicine News(10 mins):Health News:Healthpointe’s Cosmetic Laser Institute Now Providing Juvéderm Voluma XC in Anaheim 2Health News:Healthpointe’s Cosmetic Laser Institute Now Providing Juvéderm Voluma XC in Anaheim 3Health News:Needle Exchange Programs Are Delayed in Legislation, West Palm Beach Drug Rehab Comments 2Health News:Needle Exchange Programs Are Delayed in Legislation, West Palm Beach Drug Rehab Comments 3Health News:Schneider Electric Amps Up Its Use of Kinetic Data’s Enterprise Request Management Software 2Health News:Schneider Electric Amps Up Its Use of Kinetic Data’s Enterprise Request Management Software 3Health News:Schneider Electric Amps Up Its Use of Kinetic Data’s Enterprise Request Management Software 4Health News:Safeguard Scientifics Board of Directors Authorizes up to $25 Million Share Repurchase Program 2Health News:Safeguard Scientifics Board of Directors Authorizes up to $25 Million Share Repurchase Program 3Health News:Fight Alzheimer's By Taking Part in a Clinical Trial, From the July 2015 Harvard Women's Health Watch 2Health News:Fight Alzheimer's By Taking Part in a Clinical Trial, From the July 2015 Harvard Women's Health Watch 3
... (OTC,Bulletin Board: SNKTY), a Life Sciences company engaged ... of healthy aging, today announced,that effective with the ... for Pyratine-6(TM), all promotion, sales and distribution of,Pyratine-6(TM) ... Company., Phil Rose, Senetek,s Chief Operating Officer ...
... 1 UTC Power, a United,Technologies Corp. (NYSE: ... Hospital in California,s Napa Valley with its new, next-generation,fuel ... in full,production in the summer of 2009., St. ... of Adventist Health, a not-for-profit health care system operating ...
... RGEN ) announced today that Dr. Alfred L. Goldberg, ... Goldberg is currently a Professor of,Cell Biology at Harvard ... for elucidating the structure and function of the proteasome,which ... in,cells. In addition, he has made major contributions to ...
... increase as women go through menopause according to ... earlier than planned also increases through late perimenopause ... is published in the July 1 issue of ... especially problems staying asleep, are relatively prevalent concerns ...
... direct marketing promotional products company, is tapped in to a network ... products. , ... Lewiston, ME (PRWEB) July 1, 2008 ... on its Web site, Crestline Custom Imprinted Products, a direct marketing ...
... as new surgical procedures are,breaking ground daily in ... breaking ground for patients. LipoVance.com,( http://www.LipoVance.com ) is ... it is offering an unprecedented $800 coupon,toward liposuction ... "In today,s troubled economy," said Kevin Gaines ...
Cached Medicine News:Health News:Senetek Announces Plan for Promotion, Sales and Distribution of Pyratine-6(TM) 2Health News:St. Helena's Hospital Orders New Model 400kW Fuel Cell From UTC Power 2Health News:Repligen Elects Alfred L. Goldberg, Ph.D. to the Board of Directors 2Health News:Repligen Elects Alfred L. Goldberg, Ph.D. to the Board of Directors 3Health News:Sleep problems associated with menopause vary among ethnic groups 2Health News:Crestline Has Access to Hundreds of Thousands of Items 2Health News:The Shape of Things to Come: Website Gives the Lowdown on Liposuction, Pioneers the Field by Offering Consumers $800 Coupons Toward Procedures 2
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: